Literature DB >> 8971301

High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection.

H Malaty1, H M el-Zimaity, R M Genta, R A Cole, D Y Graham.   

Abstract

BACKGROUND: The combination of 120 mg of omeprazole (40 mg t.d.s.) and amoxycillin has been reported to be effective for treating H. pylori infections.
METHODS: Normal volunteers with H. pylori infection received high-dose omeprazole (40 mg t.d.s.) or lansoprazole (60 mg t.d.s.) plus amoxycillin 750 mg t.d.s. for 14 days. The studies were open label and not randomized as those receiving omeprazole plus amoxycillin had previously failed lower dose omeprazole (20 mg b.d.) plus amoxycillin therapy more than 6 months previously. Those receiving lansoprazole plus amoxycillin had not been previously treated. Four to 6 weeks after ending antimicrobial therapy, H. pylori status was determined by Genta stain of gastric mucosal biopsies.
RESULTS: Forty-three volunteers entered the study and 41 completed it. The overall success with high-dose proton pump inhibitor plus amoxycillin was 34.9%. For the individual regimens the per-protocol results were 48% (95% CI = 28-69%) with lansoprazole and 12.5% (95% CI = 2-38%) with omeprazole. Compliance was > 95% for both regimens. Side-effects were experienced by four lansoprazole and three omeprazole subjects, and caused two omeprazole subjects to withdraw. Cure rates were similar among different races and ethnic groups, between men and women, and between smokers and non-smokers. The level of the pre-treatment urea breath test also did not predict outcome.
CONCLUSION: High-dose proton pump inhibitor plus amoxycillin combinations for treatment of H. pylori infection yielded unacceptable results, as the 95% confidence intervals did not include an 80% cure rate. These combinations do not yield consistent results worldwide and cannot be recommended as primary therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971301     DOI: 10.1046/j.1365-2036.1996.77248000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.

Authors:  György M Buzás; Ilona Széles
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

4.  Rescue Therapy for Helicobacter pylori.

Authors:  Wai K. Leung; David Y. Graham
Journal:  Curr Treat Options Gastroenterol       Date:  2002-04

5.  Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?

Authors:  David Y Graham; Hong Lu; Akiko Shiotani
Journal:  Saudi J Gastroenterol       Date:  2017 Sep-Oct       Impact factor: 2.485

6.  Synthesis and Biological Evaluation of Novel 1H-Benzo[d]imidazole Derivatives as Potential Anticancer Agents Targeting Human Topoisomerase I.

Authors:  Stuti Pandey; Pragya Tripathi; Palak Parashar; Vikas Maurya; Md Zubbair Malik; Raja Singh; Pooja Yadav; Vibha Tandon
Journal:  ACS Omega       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.